menu

Medical Program: From ASCO: The Latest Research on Immunotherapy for Triple-Negative Breast Cancer

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

From ASCO: The Latest Research on Immunotherapy for Triple-Negative Breast Cancer

close
From ASCO: The Latest Research on Immunotherapy for Triple-Negative Breast Cancer
Restart
Resume
Choose a format
Media formats available:
Details
Presenters
Comments
  • Sponsored by

  • Overview

    Joining Dr. Jennifer Caudle to catch us up to speed on the latest research to come out of the 2020 ASCO Annual Meeting is Dr. David Page, medical oncologist at Providence Cancer Center in Portland, Oregon. Together, they’ll review the results from various trials investigating the use of immunotherapy for triple-negative breast cancer, including the KEYNOTE-355, ENHANCE-1, and ENCORE 602 trials.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Sponsored by

  • Overview

    Joining Dr. Jennifer Caudle to catch us up to speed on the latest research to come out of the 2020 ASCO Annual Meeting is Dr. David Page, medical oncologist at Providence Cancer Center in Portland, Oregon. Together, they’ll review the results from various trials investigating the use of immunotherapy for triple-negative breast cancer, including the KEYNOTE-355, ENHANCE-1, and ENCORE 602 trials.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 8/12/20